How to appeal a Premera Blue Cross rare disease — ert, substrate reduction, gene therapy denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Premera Blue Cross-specific note: BCBS licensee for Washington and Alaska (~2.4M members). Express Scripts PBM. WA OIC oversight. WA has strong mental health parity enforcement and surprise-billing protections that pre-date federal NSA.

What Premera Blue Cross's policy requires for rare disease — ert, substrate reduction, gene therapy

Cited policy: Anthem clinical guideline (ERT for LSD) + clinical guideline (SRT) + disease-specific (Brineura, Palynziq)

Specialist Rx; diagnosis confirmation; clinical milestones for continued coverage.

How Premera Blue Cross denies rare disease — ert, substrate reduction, gene therapy — and how to counter it

Where Premera Blue Cross pushes back: 1) 'Continuation denied — failure to demonstrate clinical response'; 2) 'Site of care must be home infusion'; 3) 'Experimental for [phenotype]' (e.g., late-onset Pompe with mild symptoms).

Counter-arguments that hold up: Continuation: cite STABILIZATION (not improvement) as treatment goal — natural history is progressive decline; Pompe Registry/ICGG/Fabry Registry data. Kishnani 2017 LOPD extension shows sustained pulmonary stabilization. FDA orphan approval for the labeled indication = standard of care, NOT experimental.

What Premera Blue Cross typically denies for rare disease — ert, substrate reduction, gene therapy

Across Premera Blue Cross's commercial and Medicare books, denials cluster around a small number of patterns. For rare disease — ert, substrate reduction, gene therapy, expect:

• WA-specific mental health parity violations
• Step therapy via Express Scripts
• Out-of-network reductions
• Specialty drug prior auth

Treatments most often denied in this category

These are the rare disease — ert, substrate reduction, gene therapy treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Pompe ERT
• Fabry ERT
• Galafold (Fabry SRT)
• Gaucher ERT
• Gaucher SRT
• MPS I ERT

How to submit the appeal to Premera Blue Cross

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Premera Blue Cross cited in the denial.
3. File the appeal through Premera Blue Cross's portal (members: https://www.premera.com ; providers: https://www.premera.com/wa/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In WA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Premera Blue Cross's prior-authorization criteria by drug: Premera Blue Cross PA criteria on ApprovalHelp.